Literature DB >> 2257229

The prognostic value of DNA-ploidy in colorectal carcinoma: a prospective study.

M Kouri1, S Pyrhönen, J P Mecklin, H Järvinen, A Laasonen, K Franssila, S Nordling.   

Abstract

One hundred and fifty-seven patients with usual colorectal cancer were analysed prospectively for DNA-ploidy, DNA-index and S-phase fraction (SPF) using flow cytometry. An abnormal DNA-stemline was observed in 68% of tumours. The patients have been followed for a median of 36 months. In univariate analysis, tumour stage was the most significant prognostic factor. After excluding patients with stage D disease, DNA-aneuploidy was significantly associated with a shorter survival and a shorter disease free survival. SPF, however, did not correlate with prognosis. In multiple samples from the same tumour there was on average a 29% difference between the highest and the lowest SPF indicating considerable heterogeneity in proliferative activity within the tumours. In diploid tumours the variation was even higher. Patients with proximal tumours as well as female patients had DNA-diploid tumours more often than the others. This may indicate that there are different, so far unknown, aetiological factors leading to different types of ploidy pattern.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257229      PMCID: PMC1971551          DOI: 10.1038/bjc.1990.420

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle.

Authors:  H Baisch; W Göhde; W A Linden
Journal:  Radiat Environ Biophys       Date:  1975-06-13       Impact factor: 1.925

2.  Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis.

Authors:  H S Goh; J R Jass; W S Atkin; J Cuzick; J M Northover
Journal:  Int J Colorectal Dis       Date:  1987-02       Impact factor: 2.571

3.  The influence of tumour cell DNA abnormalities on survival in colorectal cancer.

Authors:  N C Armitage; R A Robins; D F Evans; D R Turner; R W Baldwin; J D Hardcastle
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

4.  The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma.

Authors:  N A Scott; L M Rainwater; H S Wieand; L H Weiland; J H Pemberton; R W Beart; M M Lieber
Journal:  Dis Colon Rectum       Date:  1987-07       Impact factor: 4.585

5.  Flow cytometry of colorectal carcinoma with three-year follow-up.

Authors:  M R Melamed; W E Enker; P Banner; A J Janov; G Kessler; Z Darzynkiewicz
Journal:  Dis Colon Rectum       Date:  1986-03       Impact factor: 4.585

6.  Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas.

Authors:  P Quirke; M F Dixon; A D Clayden; P Durdey; J E Dyson; N S Williams; C C Bird
Journal:  J Pathol       Date:  1987-04       Impact factor: 7.996

7.  Tumor DNA content in the prognosis of colorectal carcinoma.

Authors:  W Kokal; K Sheibani; J Terz; J R Harada
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

8.  Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards.

Authors:  L L Vindeløv; I J Christensen; N I Nissen
Journal:  Cytometry       Date:  1983-03

9.  Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system.

Authors:  N C Davis; R C Newland
Journal:  Aust N Z J Surg       Date:  1983-06

10.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

View more
  8 in total

1.  Numerical chromosome alterations in colorectal carcinomas detected by fluorescence in situ hybridization. Relationship to 17p and 18q allelic losses.

Authors:  A Ooi; C D Huang; M Mai; I Nakanishi
Journal:  Virchows Arch       Date:  1996-07       Impact factor: 4.064

2.  Flow cytometric analysis of DNA synthetic phase fraction of the normal appearing colonic mucosa in patients with colorectal neoplasms.

Authors:  S Nakamura; J Goto; Y Kitayama; J P Sheffield; I C Talbot
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

3.  DNA index and S-phase fraction in curative resection of colorectal adenocarcinoma: analysis of prognosis and current trends.

Authors:  Han-Shiang Chen; Shyr-Ming Sheen-Chen; Chen-Chang Lu
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

4.  DNA densitometry of colorectal cancer.

Authors:  G T Deans; K Williamson; P Hamilton; M Heatley; K Arthurs; C C Patterson; B J Rowlands; T G Parks; R A Spence
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

5.  Significance of superoxide dismutase (SOD) in human colorectal cancer tissue: correlation with malignant intensity.

Authors:  A Satomi; S Murakami; T Hashimoto; K Ishida; M Matsuki; M Sonoda
Journal:  J Gastroenterol       Date:  1995-04       Impact factor: 7.527

6.  Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.

Authors:  Kai-Lin Yang; Shung-Haur Yang; Wen-Yih Liang; Ying-Ju Kuo; Jen-Kou Lin; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Huann-Sheng Wang; Shih-Ching Chang; Lee-Shing Chu; Ling-Wei Wang
Journal:  Radiat Oncol       Date:  2013-03-01       Impact factor: 3.481

7.  Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer.

Authors:  M S Wilson; C M West; G D Wilson; S A Roberts; R D James; P F Schofield
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

8.  Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience.

Authors:  R Silvestrini; I D'Agnano; A Faranda; A Costa; G Zupi; M Cosimelli; V Quagliuolo; D Giannarelli; L Gennari; R Cavaliere
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.